LGD-4033 hair loss is a growing concern among users of this unlicensed selective androgen receptor modulator (SARM), sold under the name Ligandrol. Widely used in UK fitness communities for its purported muscle-building effects, LGD-4033 is not approved by the MHRA or EMA for human use. Anecdotal reports of accelerated hair thinning and shedding during or after use are increasingly common, yet robust clinical evidence confirming a direct causal link remains absent. This article examines the biological plausibility of LGD-4033-related hair loss, individual risk factors, reported side effects, MHRA guidance, and when to seek medical advice.

Does LGD-4033 Cause Hair Loss?

There is no clinical trial evidence confirming LGD-4033 directly causes hair loss, though anecdotal reports of hair thinning exist and a biological link is theoretically plausible given its androgen receptor activity.

Not sure if this is normal? Chat with one of our pharmacists →

LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) that has attracted significant interest in fitness and bodybuilding communities for its purported muscle-building effects. However, its relationship with hair loss is a subject of growing concern among users and clinicians alike.

There is currently no clinical trial evidence confirming that LGD-4033 directly causes hair loss in humans. A number of anecdotal reports from users describe accelerated hair thinning or shedding during or after a cycle of LGD-4033, but these accounts are observational and unverified; they should not be interpreted as proof of causation. The possibility of a link is biologically plausible given the compound's mechanism of action (see below), but this remains unproven in robust human studies.

LGD-4033 is not approved for human use by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, nor by the European Medicines Agency (EMA). It was originally developed for potential therapeutic use in conditions such as muscle wasting and osteoporosis, but it has not completed the clinical development process required for a marketing authorisation. Any use outside of a clinical trial setting therefore carries inherent and poorly characterised risks, including potential effects on hair growth cycles. The MHRA advises consumers to be cautious about purchasing unlicensed products online.

How SARMs May Affect Hair Follicles and Androgen Receptors

LGD-4033 may theoretically bind to androgen receptors in scalp follicles, potentially accelerating miniaturisation in genetically susceptible individuals, though this has not been demonstrated in clinical studies.

To understand why LGD-4033 might theoretically contribute to hair loss, it is helpful to consider how androgens interact with hair follicles. Dihydrotestosterone (DHT), a potent androgen derived from testosterone, is well established as a key driver of androgenetic alopecia (male and female pattern hair loss). DHT binds to androgen receptors in genetically susceptible hair follicles, causing them to miniaturise over time — a process that progressively shortens the hair growth cycle. This pathophysiology is described in detail by the British Association of Dermatologists (BAD) and on the NHS Hair Loss pages.

Worried about interactions with other medications? Speak to one of our pharmacists →

SARMs like LGD-4033 are designed to selectively bind to androgen receptors, ideally targeting muscle and bone tissue while sparing others. However, the selectivity of SARMs is not absolute. It is theoretically possible that LGD-4033 could bind to androgen receptors in scalp follicles — even partially — and thereby trigger or accelerate follicular miniaturisation in individuals who are genetically predisposed to hair loss. This mechanism has not been demonstrated in clinical studies of LGD-4033 and should be understood as a theoretical concern rather than an established finding.

A published phase I multiple-ascending-dose study of LGD-4033 in healthy men demonstrated dose-dependent suppression of the hypothalamic-pituitary-gonadal (HPG) axis, with reductions in total testosterone, sex hormone-binding globulin (SHBG), and HDL cholesterol. This hormonal disruption can alter the balance of androgens in the body in unpredictable ways. Some users report increased hair shedding after stopping LGD-4033, which may be consistent with telogen effluvium — a form of diffuse, temporary hair loss triggered by physiological stress or hormonal change. However, a direct causal link between LGD-4033 use and telogen effluvium has not been established in clinical research, and this explanation remains speculative.

Reported Side Effects of LGD-4033 in the UK

Documented side effects of LGD-4033 include testosterone suppression, drug-induced liver injury, HDL cholesterol reduction, mood changes, and hair thinning, with product purity also a significant concern due to lack of regulation.

Although LGD-4033 is not a licensed medicine in the UK, it is widely available through online retailers and grey-market supplement suppliers. This accessibility means that adverse effects are increasingly being reported, both informally through online communities and, in some cases, through clinical encounters.

Beyond hair thinning, users in the UK have reported a range of side effects associated with LGD-4033 use, including:

• Testosterone suppression — the phase I clinical trial of LGD-4033 confirmed dose-dependent HPG-axis suppression. Some users self-administer so-called 'post-cycle therapy' (PCT) in an attempt to restore hormonal function; however, PCT is not evidence-based, is not recommended outside specialist medical supervision, and carries its own risks. Anyone experiencing symptoms of hormonal suppression should seek advice from a GP or endocrinologist rather than self-treating.

• Elevated liver enzymes and drug-induced liver injury (DILI) — cases of LGD-4033-associated hepatotoxicity have been documented in peer-reviewed medical literature and are catalogued in the NIH LiverTox database. This is a serious potential risk.

• Mood changes — including low mood, irritability, and fatigue, likely linked to hormonal suppression.

• Cardiovascular changes — including reductions in HDL cholesterol, as reported in the phase I clinical trial.

• Headaches and nausea — cited in early-phase clinical trial data.

Hair loss, while not universally experienced, is among the more frequently discussed side effects in user communities. The severity appears to vary considerably between individuals, suggesting that genetic predisposition plays a significant role.

Because LGD-4033 is unregulated, product purity and dosage accuracy cannot be guaranteed. Independent analytical studies — including investigations published in peer-reviewed journals — have found that products sold as SARMs frequently contain inaccurate quantities of the stated compound, undisclosed anabolic agents, or other contaminants. This further complicates the side effect profile.

Anyone who suspects they have experienced an adverse reaction to LGD-4033 or any other unlicensed product should report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This helps regulators monitor emerging safety signals.

Who May Be at Greater Risk of Hair Thinning

Those with a personal or family history of androgenetic alopecia, older users, and those combining LGD-4033 with other androgens face the greatest theoretical risk of hair thinning.

Not everyone who uses LGD-4033 will experience hair loss, and understanding individual risk factors can help contextualise the concern. The most significant predictor of androgen-related hair loss is genetic susceptibility — specifically, a personal or family history of androgenetic alopecia on either the maternal or paternal side.

Research suggests that variants in the androgen receptor gene (located on the X chromosome) that confer heightened sensitivity to androgens are associated with increased risk of pattern hair loss. For individuals with such a predisposition, even modest androgen receptor stimulation — such as that theoretically provided by a SARM — may be sufficient to accelerate follicular miniaturisation that would otherwise have occurred more gradually with age. It should be noted, however, that routine genetic testing for androgen receptor variants is not part of standard UK clinical care, and the precise contribution of any single genetic variant to hair loss risk is complex and not fully characterised.

Other factors that may increase vulnerability include:

• Age — older users may already have some degree of follicular miniaturisation, making them more susceptible.

• Baseline hormone levels — those with naturally higher androgen activity may experience more pronounced effects.

• Concurrent supplement use — combining LGD-4033 with other androgens, prohormones, or anabolic steroids significantly increases the risk of androgenic side effects and hormonal disruption.

• Duration and dose — longer cycles and higher doses are associated with greater HPG-axis suppression.

Women who use LGD-4033 — a practice that does occur, despite the compound being entirely unlicensed — may be at particular risk of androgenic side effects, including hair thinning and virilisation (such as voice changes or increased body hair), given that female physiology can be sensitive to even small increases in androgen receptor activity. LGD-4033 should not be used during pregnancy or when trying to conceive, as the effects on fetal development are unknown and potentially harmful.

MHRA Guidance on SARMs and Consumer Safety in the UK

The MHRA classifies SARMs as unlicensed medicines; their sale for human use is unlawful in the UK, and purchased products carry no guarantee of quality, safety, or accurate dosage.

The MHRA classifies SARMs as unlicensed medicines when sold for human consumption in the UK. Under the Human Medicines Regulations 2012, the sale or supply of unlicensed medicines for human use is unlawful. Possession of LGD-4033 for personal use is not generally a criminal offence, but products purchased outside the licensed medicines supply chain are not subject to quality, safety, or efficacy oversight — meaning there is no assurance of what they actually contain.

The MHRA has warned consumers that products sold as SARMs online may:

• Contain inaccurate doses — independent laboratory testing has frequently found that SARM products contain more or less of the stated compound than labelled.

• Be contaminated — with other controlled substances, heavy metals, or undisclosed anabolic agents.

• Carry unknown long-term risks — as human safety data beyond short-term clinical trials is largely absent.

The World Anti-Doping Agency (WADA) includes SARMs on its Prohibited List, and UK Anti-Doping (UKAD) enforces this prohibition for athletes subject to testing. Athletes should consult the UKAD website and the WADA Prohibited List before using any supplement.

Healthcare professionals encountering patients who have used LGD-4033 should be aware that standard drug interaction databases may not capture SARM-related interactions, and clinical judgement alongside specialist referral may be necessary when managing complications. Suspected adverse reactions should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

When to Seek Medical Advice About Hair Loss

Anyone experiencing hair loss after LGD-4033 use should see a GP, who can investigate androgenetic, hormonal, or other causes; urgent same-day care is needed if symptoms of liver injury such as jaundice occur.

Hair loss associated with SARM use — whether temporary or progressive — warrants medical evaluation, particularly if it is causing distress or appears to be worsening. A GP is the appropriate first point of contact and can help determine whether the hair loss is androgenetic, telogen effluvium, or related to another underlying cause such as thyroid dysfunction, nutritional deficiency (including low ferritin or iron deficiency), or autoimmune conditions such as alopecia areata.

Seek urgent same-day medical attention if you experience any of the following, as they may indicate serious liver injury or severe hormonal disturbance:

• Jaundice (yellowing of the skin or whites of the eyes)

• Dark urine or pale stools

• Severe or persistent abdominal pain, particularly in the upper right side

• Confusion or significant changes in mental state

• Severe or rapidly worsening low mood

You should also seek prompt (non-urgent) medical advice if you notice:

• Sudden or rapid hair shedding — particularly in the weeks following LGD-4033 use.

• Patchy hair loss — which may suggest alopecia areata rather than androgen-related thinning.

• Scalp changes — such as redness, scaling, or tenderness, which may indicate a dermatological condition.

• Systemic symptoms — including fatigue, low mood, reduced libido, or breast tenderness, which may indicate hormonal suppression.

It is important to be honest with your GP about SARM use, as this information is clinically relevant and will not result in legal consequences for personal possession. Blood tests that may be appropriate include full blood count, serum ferritin, liver function tests, testosterone, LH, FSH, and thyroid function, depending on the clinical picture. Referral to a dermatologist or endocrinologist may be warranted in more complex cases.

For those concerned about ongoing hair loss, the NHS provides guidance on evidence-based treatment options. Topical minoxidil is available over the counter (OTC) for both men and women and has an established evidence base for androgenetic alopecia. Oral finasteride 1 mg for male pattern hair loss is generally available via private prescription rather than routinely on the NHS, and is contraindicated in women who are pregnant or may become pregnant. Treatment options should be discussed with a GP, dermatologist, or pharmacist, with reference to current BNF guidance and NHS Hair Loss information. The British Association of Dermatologists also provides patient information on male and female pattern hair loss.

Frequently Asked Questions